Myovant Sciences (NYSE: MYOV), a healthcare company focused on
developing innovative treatments for women's health and prostate
cancer, and Evidation Health, a health and measurement company that
helps life sciences and healthcare companies understand how
everyday behavior and health interact, today announced a
collaboration to conduct a digital study on the prevalence and
impact of menstrual symptoms experienced by women in the U.S., as
well as an evaluation of the education and attitudes of women and
men regarding menstruation.
The digital study launched today involves over 20,000 people,
who will receive survey questions via Evidation’s health app,
Achievement, which engages with a population of over 3 million
people across the U.S..
“Historically, women’s health research has been underfunded,
undervalued, and ignored, which has led to major gaps in scientific
understanding – especially around what is ‘normal’ for menstrual
symptoms like bleeding and pain,” said Lynn Seely, M.D., President
and CEO of Myovant. “This partnership demonstrates Myovant’s
commitment to uncovering critical insights that will advance
women’s health and meaningfully contribute to education and
conversations around menstruation.”
Myovant and Evidation will present the results from this
collaboration later this year with the goal to raise awareness
about common but underappreciated symptoms like heavy menstrual
bleeding and menstrual pain, which can indicate diseases like
uterine fibroids and endometriosis.
The survey questions are designed to assess the prevalence and
impact of heavy menstrual bleeding and menstrual pain. These
symptoms are often overlooked as normal features of menstruation.
Yet uterine fibroids and endometriosis affect over 20 million women
in the U.S.1, cost the U.S. billions each year in healthcare costs
and lost productivity2, and often take years to diagnose.3 Disease
state awareness is critical to combating this delay.
Evidation’s unique platform connects with smartphones and
connected sensors to enrich survey responses with passive
behavioral data, such as sleep, heart rate, and physical activity.
Data is only collected with explicit permission, and Achievement
members have control over how their data is collected, used, and
shared.
“By pairing Myovant’s clinical expertise in women’s health with
Evidation’s platform and diverse population access, we hope to lay
the groundwork for leveraging and improving digital tools to
measure menstrual symptoms, so that we may better understand them
in the context of women’s overall health and how they contribute to
daily experiences,” said Christine Lemke, Co-Founder and President
of Evidation. “The underrepresentation of women in clinical
research and lack of studies on women’s health issues are
staggering, and this is a first step in beginning to close these
gaps.”
In the portion of the survey designed to assess education and
attitudes regarding menstruation, both female and male responders
will be asked about their comfort level and confidence in talking
about menstruation and their perception of period stigma. Questions
for this section were developed in collaboration with Myovant’s
partner PERIOD. Inc., a non-profit organization committed to ending
period stigma.
“The first step to overcoming the stigma around menstruation is
understanding what women and men know and don’t know about
periods,” said Nadya Okamoto, Founder and Executive Director of
PERIOD. “At PERIOD, our goal is to change the way people talk about
periods, and this survey will give us important insights into the
attitudes and knowledge gaps that need to be addressed to change
the status quo.”
About Myovant SciencesMyovant
Sciences aspires to be the leading healthcare company focused
on developing innovative treatments for women's health and prostate
cancer. Myovant's lead product candidate is relugolix, an oral,
once daily small molecule that acts as a GnRH receptor antagonist.
Myovant has three late-stage clinical programs for relugolix
ongoing in uterine fibroids, endometriosis and prostate cancer.
Myovant is also developing MVT-602, an oligopeptide kisspeptin-1
receptor agonist, that has completed a Phase 2a study for the
treatment of female infertility as part of assisted
reproduction. Takeda Pharmaceuticals International
AG granted Myovant an exclusive, worldwide license to develop
and commercialize relugolix (excluding Japan and certain
other Asian countries) and an exclusive license to develop and
commercialize MVT-602 in all countries worldwide. For more
information, please visit Myovant's website
at www.myovant.com. Follow @Myovant on Twitter and LinkedIn
(https://www.linkedin.com/company/myovant-sciences).
About EvidationEvidation Health is a new kind
of health and measurement company that provides the world’s most
innovative life sciences and health care companies the technology
and expertise they need to understand how everyday behavior and
health interact. The volume of behavior data generated from
smartphones and connected sensors — including wearables and medical
devices — has opened up new ways to analyze individuals’ behavior
and health in real time, unlocking insights into what medicines and
treatments work best and spotting significant changes in health
earlier. The scale and utility of everyday behavior data has the
potential to be one of the most transformative forces in medicine,
and Evidation Health is leading the way.
Over the years, Evidation has built the largest, most diverse
virtual pool of research participants through its proprietary and
popular app, Achievement. With a direct and trusted relationship
with more than 3 million individuals, its deep research expertise,
and its data platform, Evidation can undertake real world research
for life sciences and health care companies — and, ultimately,
transform how health is measured and how diseases are identified,
treated, and monitored. Founded in 2012, Evidation Health is
headquartered in San Mateo, Calif., with additional offices in San
Francisco and Santa Barbara, Calif. To learn more,
visit evidation.com, or follow us on
Twitter @evidation.
About PERIOD. Inc.PERIOD's mission is to end
period poverty and stigma through service, education, and
advocacy. Through a network of almost 400 chapters in all 50
states PERIOD distributes menstrual products to people in need;
educates to change the way people think, talk, and learn about
periods; and advocates for systemic change to ensure that menstrual
products are free and available for everyone. PERIOD was
founded in 2014 by Nadya Okamoto and Vincent Forand when they were
juniors in high school. Since then, PERIOD has served over a
half million periods. For more information, please
visit www.period.org.
Myovant Media Contact:Sheryl Seapy W2O
Pure sseapy@purecommunications.com949.903.4750
Evidation Media Contact:Rachel
Katzevidation@crosscutstrategies.com202-792-7200
1 Bulun. NEJM. 2009; Stewart. NEJM. 2015.2 Simeons et al. Hum
Reprod Update. 2007; Cardozo et al. Am J Obstet Gynecol. 2012.3
Agarwal et al. Am J Obstet Gynecol; 2019. Marsh et al. Journal of
Women’s Health. 2018.
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024